search
Back to results

The Effects of INP on Peripheral Circulation in Dialysis Patients and Patients With PAD and Leg Ulcers

Primary Purpose

Renal Disease, Peripheral Arterial Disease, Arterial Leg Ulcers

Status
Terminated
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
FlowOx™
Sponsored by
Oslo University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Renal Disease focused on measuring Arterial leg ulcers, Intermittent Negative Pressure, Peripheral Circulation, Wound healing, Peripheral blood flow

Eligibility Criteria

18 Years - 96 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Able and willing to provide informed consent
  • Age: 18-96 years
  • Affected foot/shoe size <46 (approximate foot length< 29,5 cm)
  • Receiving hemodialysis ≥3 times per week for 1 hour per treatment OR
  • Peripheral arterial disease and leg ulcer

Exclusion criteria:

  • Incapable to consent voluntarily, i.e. patients who are not able to consent due to their mental status, or who are not willing or able to perform the negative pressure therapy in a sitting position
  • Not adhering to the INP therapy program
  • Patients with an expected life-span less than 3 months
  • Patients in whom the remaining limb is non-functional, for example due to previous stroke
  • Patients in which a deep venous thrombosis or pulmonary embolism is suspected
  • Limbs with uncontrolled infection
  • Previous lumbar sympathectomy
  • Bilateral amputation of lower extremity

Sites / Locations

  • Oslo University Hospital - Ullevål, Department of Nephrology

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

single-case design

Arm Description

The study design will be a non-randomized clinical trial with single-subject baseline design (also called single-case baseline design) where each patients act as their own controls: Observations (A) will be taken before and after a 8-week intervention period. We plan to introduce a 4-week INP-treatment period ('FlowOx™) (B) using the same outcome variables that were used as baseline measures. If the patient demonstrates improvements in outcome variables after the first treatment period (B1), the patient will be asked to continue INP therapy for another 4-week period, before a final assessment after a total of 8-week intervention period (B2) (A-B-B design).

Outcomes

Primary Outcome Measures

Segmental Skin Perfusion Pressure
Fully automated and quantitative evaluation of microcirculatory perfusion in the skin of the foot and leg (Sensilase, Vasamed, USA). Multiple levels can be assessed on limbs; bilateral measurement helps to manage test time Not susceptible to interference effects from medial calcification Requires use of pressure cuffs to occlude blood flow for specified time period in order to evaluate reactive hyperemic response to controlled release of pressure Graphical output of pressure and perfusion during cuff deflation indicates the pressure (mmHg) at which skin perfusion is found to return in addition to pressure contour
Life Quality (SF-12 or EQ-5D-5L)
SF-12 or EQ-5D-5L
Pulse Volume Recording / segmental volume plethysmography (PVR)
PVR shows variations in the volume of blood passing through a limb during each cardiac cycle. The instrument that will be used to measure PVR for this study is Sensilase (Vasamed, USA) OR MacroLab (STR Teknikk, strteknikk.no, Aalesund, Norway). Multiple levels can be assessed on limbs. The measures are not susceptible to interference effects from medial calcification.
Wound healing (Measuring wound diameter and length)
Measurement of healing to provide a means by which progress over time to wound closure can be identified. A wound nurse will take pictures at study start and at follow-up.
Ankle-Brachial Pressure Index (ABPI)
The ratio of the blood pressure at the ankle (dorsal pedis artery/posterior tibial artery) to the blood pressure in the upper arm (brachial artery)

Secondary Outcome Measures

Full Information

First Posted
December 2, 2015
Last Updated
April 4, 2017
Sponsor
Oslo University Hospital
Collaborators
Otivio AS, University of Oslo
search

1. Study Identification

Unique Protocol Identification Number
NCT02622308
Brief Title
The Effects of INP on Peripheral Circulation in Dialysis Patients and Patients With PAD and Leg Ulcers
Official Title
The Effects of Intermittent Negative Pressure on Peripheral Circulation in Dialysis Patients and Patients With Lower Limb Ischemia and Leg Ulcers
Study Type
Interventional

2. Study Status

Record Verification Date
August 2016
Overall Recruitment Status
Terminated
Why Stopped
Terminated due to lack of recruitment
Study Start Date
March 11, 2016 (Actual)
Primary Completion Date
April 11, 2016 (Actual)
Study Completion Date
December 7, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Oslo University Hospital
Collaborators
Otivio AS, University of Oslo

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This experimental study will look at the effects of INP therapy for two patient groups: 1) patients with reduced peripheral circulation and chronic wounds in patients with renal disease (dialysis patients); 2) and peripheral arterial disease and leg ulcers. The project is designed as a non-randomized clinical trial with single-subject multiple baseline design. Also the intervention will be subjected on the same leg for each individual throughout the study period. The other leg will act as a control. A baseline measure with patient history collection will be performed before a four-week intervention period. These measures include: Segmental pulse-volume-recording, Segmental skin perfusion pressure with a laser Doppler sensor and a pressure cuff to evaluate reactive hyperemia (Sensilase, Väsamed) and a health survey (SF-12/EQ-5D-5L) or similar. After four weeks and eight weeks of intervention, the same tests will be repeated. A final follow-up test will be two weeks after cessation of the intermittent negative pressure intervention. The study will look at the effect of INP on renal failure patients who are given dialysis at a dialysis center located at Oslo University Hospital, Ullevål. Otivio AS has supplied the FlowOx devices and provided the necessary training to perform this project. Outcome variables assessed before, during and after the 10-week study period will be: wound healing, quality of life, skin perfusion pressure and segmental pulse-volume recording. The aim of this project is to prospectively examine and elucidate the effect of intermittent negative pressure therapy on clinically relevant measures related to the reduction of peripheral macro- and microcirculation in patients with renal failure undergoing dialysis treatment. The hypothesis of the study is: Application of INP in patients with renal failure, by the use of the FlowOx™ device, will improve wound healing and peripheral circulation in the foot compared to before treatment (baseline) in patients undergoing dialysis treatment. Application of INP in patients with PAD, by the use of the FlowOx™ device, will improve macro- and microcirculation and wound healing in the foot compared to before treatment (baseline) in patients with chronic wounds.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Renal Disease, Peripheral Arterial Disease, Arterial Leg Ulcers
Keywords
Arterial leg ulcers, Intermittent Negative Pressure, Peripheral Circulation, Wound healing, Peripheral blood flow

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
4 (Actual)

8. Arms, Groups, and Interventions

Arm Title
single-case design
Arm Type
Experimental
Arm Description
The study design will be a non-randomized clinical trial with single-subject baseline design (also called single-case baseline design) where each patients act as their own controls: Observations (A) will be taken before and after a 8-week intervention period. We plan to introduce a 4-week INP-treatment period ('FlowOx™) (B) using the same outcome variables that were used as baseline measures. If the patient demonstrates improvements in outcome variables after the first treatment period (B1), the patient will be asked to continue INP therapy for another 4-week period, before a final assessment after a total of 8-week intervention period (B2) (A-B-B design).
Intervention Type
Device
Intervention Name(s)
FlowOx™
Other Intervention Name(s)
Intermittent negative pressure device
Intervention Description
FlowOx™ uses intermittent negative and atmospheric pressure, and is intended for use as an adjunct non-invasive therapy for the treatment of reduced peripheral circulation. Negative pressure cycles are created by alternating between removing air and venting the vacuum-chamber to atmospheric pressure. The vacuum cycle is controlled by the Control Unit (Pump). FlowOx™ is designed to assists wound healing indirectly by improving blood flow to the affected limb and augmenting the wound healing effect of the contact dressings and any associated medication. Treatment is planned to be applied while the participants are seated and it does not interfere with other activities normally enjoyed while seated. Treatment is recommended for one to two hours per session aiming to improve blood flow in the affected area and thus the clinical outcomes.
Primary Outcome Measure Information:
Title
Segmental Skin Perfusion Pressure
Description
Fully automated and quantitative evaluation of microcirculatory perfusion in the skin of the foot and leg (Sensilase, Vasamed, USA). Multiple levels can be assessed on limbs; bilateral measurement helps to manage test time Not susceptible to interference effects from medial calcification Requires use of pressure cuffs to occlude blood flow for specified time period in order to evaluate reactive hyperemic response to controlled release of pressure Graphical output of pressure and perfusion during cuff deflation indicates the pressure (mmHg) at which skin perfusion is found to return in addition to pressure contour
Time Frame
8 weeks
Title
Life Quality (SF-12 or EQ-5D-5L)
Description
SF-12 or EQ-5D-5L
Time Frame
8 weeks
Title
Pulse Volume Recording / segmental volume plethysmography (PVR)
Description
PVR shows variations in the volume of blood passing through a limb during each cardiac cycle. The instrument that will be used to measure PVR for this study is Sensilase (Vasamed, USA) OR MacroLab (STR Teknikk, strteknikk.no, Aalesund, Norway). Multiple levels can be assessed on limbs. The measures are not susceptible to interference effects from medial calcification.
Time Frame
8 weeks
Title
Wound healing (Measuring wound diameter and length)
Description
Measurement of healing to provide a means by which progress over time to wound closure can be identified. A wound nurse will take pictures at study start and at follow-up.
Time Frame
8 weeks
Title
Ankle-Brachial Pressure Index (ABPI)
Description
The ratio of the blood pressure at the ankle (dorsal pedis artery/posterior tibial artery) to the blood pressure in the upper arm (brachial artery)
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
96 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Able and willing to provide informed consent Age: 18-96 years Affected foot/shoe size <46 (approximate foot length< 29,5 cm) Receiving hemodialysis ≥3 times per week for 1 hour per treatment OR Peripheral arterial disease and leg ulcer Exclusion criteria: Incapable to consent voluntarily, i.e. patients who are not able to consent due to their mental status, or who are not willing or able to perform the negative pressure therapy in a sitting position Not adhering to the INP therapy program Patients with an expected life-span less than 3 months Patients in whom the remaining limb is non-functional, for example due to previous stroke Patients in which a deep venous thrombosis or pulmonary embolism is suspected Limbs with uncontrolled infection Previous lumbar sympathectomy Bilateral amputation of lower extremity
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jonny Hisdal, PhD
Organizational Affiliation
Oslo University Hospital - Aker
Official's Role
Principal Investigator
Facility Information:
Facility Name
Oslo University Hospital - Ullevål, Department of Nephrology
City
Oslo
Country
Norway

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

The Effects of INP on Peripheral Circulation in Dialysis Patients and Patients With PAD and Leg Ulcers

We'll reach out to this number within 24 hrs